Hybrid Molecular Imaging Using PET/CT and PET/MRI in Inflammatory Bowel Disease: Current Applications, Challenges, and Future Perspectives Authors: Yuqin Li, Min Wang, Bin Liu, Zijun Yuan, Wenbo Yang, Wenchun Yao, Yongxin Yuan Published: 2026 ABSTRACT Hybrid molecular imaging is increasingly recognized as a valuable tool for the precision management of inflammatory bowel disease (IBD). Driven by the treat-to-target paradigm, the noninvasive quantification of transmural inflammation and the accurate differentiation of stricture phenotypes remain key clinical challenges. Current evidence indicates that although 2-deoxy-2-18F-fluoro-D-glucose (18F-FDG) positron emission tomography (PET) can effectively quantify the overall inflammatory burden, the integration of fibroblast activation protein inhibitor (FAPI)-targeted PET imaging provides important complementary value for characterizing fibro-inflammatory remodeling and distinguishing fibrotic strictures. By combining high metabolic sensitivity with high-resolution multiparametric soft-tissue characterization, PET/magnetic resonance imaging (MRI) has demonstrated potential advantages in assessing penetrating complications and facilitating longitudinal therapeutic monitoring. Pediatric and young adult patients requiring long-term follow-up may derive substantial benefit from the reduced radiation exposure offered by integrated PET/MRI systems. To overcome conventional method limitations, including physiologic intestinal uptake and attenuation-correction artifacts, the field is actively exploring novel molecularly targeted tracers, ultra-low-dose long-axial-field-of-view whole-body systems, and artificial intelligence-based image reconstruction techniques. Given that substantial current evidence is derived from small, single-center cohorts and experimental studies, these advanced modalities currently serve as adjunctive, problem-solving tools rather than routine replacements for standard endoscopy or conventional cross-sectional imaging. This review comprehensively evaluates the clinical performance, applicability, and translational barriers of hybrid molecular imaging in IBD, underscoring the urgent need to establish standardized, multicenter consensus protocols that can guide its future implementation in individualized therapeutic strategies. Introduction Inflammatory bowel disease (IBD), primarily comprising Crohn’s disease (CD) and ulcerative colitis (UC), is a group of immune-mediated disorders characterized by chronic, relapsing inflammation of the gastrointestinal tract [1,2]. In recent years, its global incidence has continued to rise [3]. The disease typically follows a course marked by alternating remission and relapse. Inadequate long-term control of inflammation can lead to irreversible structural damage to the bowel wall. This damage often results in strictures, penetrating complications such as fistulas and abscesses, and an increased risk of malignancy [1,4]. Therefore, accurate assessment of disease activity, extent of involvement, and treatment response is essential to optimize individualized management and improve long-term patient outcomes [5]. At present, ileocolonoscopy combined with histopathological biopsy remains the gold standard for diagnosis of IBD [6]. However, endoscopic examination is invasive and inherently limited in its ability to assess small-bowel involvement and transmural disease. Consequently, it does not adequately meet the demands of long-term, high-frequency longitudinal follow-up [6]. Noninvasive cross-sectional imaging techniques, such as computed tomography enterography (CTE) and magnetic resonance enterography (MRE), can effectively evaluate bowel wall thickening and extraintestinal complications, thus providing important information complementary to endoscopy findings [7]. MRE is particularly suitable for disease monitoring because it does not involve ionizing radiation and offers excellent soft-tissue contrast [6]. Nevertheless, conventional morphologic imaging has limited sensitivity for detection of early, mild inflammation. Furthermore, it remains inadequate for distinguishing inflammation-predominant from fibrosis-predominant components within strictures [8]. This limitation restricts its role in guiding decisions regarding medical treatment escalation or the timing of surgical intervention [8]. Currently, there is a pressing clinical need for dynamic monitoring of disease activity, comprehensive assessment of transmural remodeling, and characterization of stricture phenotypes [9]. To address these needs, the development of imaging techniques capable of noninvasively reflecting tissue activity and the molecular microenvironment has become an important direction in IBD research [9]. Against this background, positron emission tomography (PET) provides molecular-level information beyond anatomic morphology by visualizing tissue metabolism and immune activation in vivo [10]. Through continuing advances in multimodal imaging, integrated PET/CT and PET/magnetic resonance imaging (PET/MRI) enable the spatial fusion of molecular signals with high-resolution anatomic structures. This integration greatly expands the potential role of PET in IBD [11]. In current practice, PET/CT is primarily valuable for lesion localization and the detection of complex extraintestinal complications [11]. However, PET/MRI may offer complementary advantages in selected scenarios. By combining multiparametric imaging capabilities with extremely low radiation exposure, PET/MRI provides distinct advantages for the detailed characterization of transmural inflammatory features and the long-term follow-up of pediatric patients [11,12]. Existing reviews have often addressed conventional cross-sectional imaging, PET/MRI, or molecular imaging tracers as separate topics. To address this gap and synthesize emerging evidence, this review examines the roles of hybrid molecular imaging, including PET/CT and PET/MRI, in IBD. Within this clinically oriented framework, we integrate evidence on established 2-deoxy-2-18F-fluoro-D-glucose (18F-FDG) imaging, fibroblast activation protein inhibitor (FAPI)-targeted imaging, and selected technical advances. Our discussion is organized around key clinical scenarios, including lesion localization, inflammatory burden assessment, fibrosis-oriented stricture phenotyping, treatment response monitoring, and the evaluation of complex complications. Finally, we discuss current limitations and future directions in the context of practical IBD management. Pathophysiological Basis of IBD The active phase of IBD is characterized by persistent immune cell infiltration and the release of proinflammatory mediators within the intestinal mucosa and submucosa [13]. Activated inflammatory cells undergo immunometabolic reprogramming, such that energy metabolism shifts from oxidative phosphorylation to glycolysis, thereby substantially increasing local glucose uptake [14]. These molecular alterations often precede anatomic abnormalities [15]. Concurrently, chronic transmural inflammation induces the transition of fibroblasts into myofibroblasts. This process mediates excessive extracellular matrix deposition and drives fibrotic remodeling of the bowel wall [16,17]. Accordingly, IBD lesions undergo a continuous biological process that evolves from heightened inflammatory metabolism to stromal remodeling [9]. Such progression provides the pathophysiological basis for stratified assessment via molecular imaging [9]. Mechanistic Rationale of Molecular Tracers 18F-FDG PET 18F-FDG is currently the most widely used PET tracer in clinical practice, and its uptake is closely associated with local glycolytic activity in tissues [10]. In active IBD lesions, enhanced immune cell metabolism drives increased 18F-FDG uptake, generating a detectable signal [10]. Quantitative PET parameters, including the maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), and related indices, may facilitate semiquantitative assessment of intestinal inflammatory activity and overall disease burden, thereby supporting disease activity evaluation and longitudinal monitoring [10,11]. However, FDG uptake is not specific to IBD-related inflammation; physiologic intestinal uptake and bowel peristalsis may reduce target-to-background contrast and introduce interpretive difficulties, thus limiting the specificity, accuracy, and reproducibility of 18F-FDG PET assessment [18–20]. FAPI PET As an emerging targeted imaging modality, FAPI PET enables dynamic characterization of intestinal stromal remodeling and fibrotic progression through specific binding to fibroblast activation protein (FAP) expressed on the surface of activated myofibroblasts [17,21]. In IBD, particularly CD, inflammation and fibrosis often coexist in a complex, intertwined manner [22]. FAPI PET can objectively characterize the fibrosis-predominant component and remodeling activity within lesions. Furthermore, the degree of tracer uptake is significantly correlated with histologic fibrosis grade [22,23]. Compared with conventional morphologic imaging, FAPI PET adds a functional dimension by assessing stromal activity [23]. This capability facilitates the identification of fibroinflammatory stricture phenotypes. Additionally, it provides an objective quantitative basis for assessing chronic reparative processes, such as transmural healing [24,25]. Ultimately, these advantages support the transition toward individualized precision management of CD [9]. Novel Mechanism-Targeted Tracers Beyond the metabolic axis characterized by 18F-FDG and the stromal remodeling axis delineated by FAPI, novel experimental PET tracers in IBD are expanding to target specific pathogenic mechanisms [10]. The development of these tracers is primarily directed toward the in vivo visualization and quantitative characterization of several key biological processes. These targets include immune cell recruitment and homing [26], infiltration of specific immune cell subsets [16], expression of key inflammatory mediators and therapeutic targets [27], and downstream effector pathways [10]. Emerging studies have also begun to explore targeted imaging strategies for pathological angiogenesis and intestinal microbial dysbiosis [28,29]. Overall, most of these tracers remain at the preclinical or early translational stage. They are currently used primarily to characterize the inflammatory microenvironment, providing complementary information for lesion characterization and disease activity assessment [10]. Although they hold translational potential for prognostic stratification, treatment response prediction, and companion diagnostics, their clinical utility requires validation in prospective studies and standardized workflows [9,30]. Clinical Applications of PET/CT Diagnosis and Lesion Localization PET/CT can help delineate the inflammatory metabolic burden throughout the bowel. When integrated with cross-sectional anatomic information and clinical parameters, it can improve lesion localization and assessment of disease extent, particularly in CD with a skip-lesion distribution [31]. 18F-FDG PET/CT can identify inflammation-related metabolic abnormalities when morphologic changes are inconspicuous, thus providing complementary information for lesion localization [32]. It also serves as a useful noninvasive tool for assessing disease extent. This role is supported by the findings of a meta-analysis by Treglia et al [33], which included 219 patients and showed a pooled sensitivity of 85% and pooled specificity of 87% for the diagnosis of IBD. However, FDG imaging is frequently confounded by physiologic bowel uptake, peristalsis, and intraluminal contents. Furthermore, heterogeneity in acquisition parameters and interpretation thresholds across studies complicates its clinical application. Therefore, the establishment of standardized image acquisition and quantification protocols remains a prerequisite for routine clinical implementation [34,35]. Compared with FDG metabolic imaging, emerging FAPI tracers have demonstrated higher lesion contrast in selected studies [31]. A recent prospective head-to-head study revealed the superior diagnostic accuracy of 68Ga-FAPI-04 PET/CT over 18F-FDG PET/CT for detecting newly diagnosed or recurrent CD lesions. Specifically, 68Ga-FAPI-04 achieved a higher area under the curve (AUC; 0.92 vs 0.87), sensitivity (90.0% vs 85.0%), and specificity (93.0% vs 88.4%) [31]. These findings suggest improved performance in assessing disease distribution and the extent of bowel involvement [31]. A comprehensive meta-analysis by Abdlkadir et al [22], including 547 patients and 1935 bowel segments, further supported this advantage. The pooled sensitivity, specificity, and accuracy of FAPI PET (92%, 93%, and 96%, respectively) were significantly higher than those of 18F-FDG PET (76%, 81%, and 85%, respectively). Indirect comparisons from this meta-analysis suggested that the overall diagnostic performance of FAPI PET was approximately 2-fold higher than that of 18F-FDG PET [22]. However, this apparent advantage should be interpreted cautiously and confirmed in larger head-to-head studies. Additionally, Chen et al [36] showed that 68Ga-FAPI-04 PET/CT had higher diagnostic performance than conventional CTE for detection of endoscopically involved bowel segments. Its ability to detect lesions throughout the gastrointestinal tract without fasting or specialized bowel preparation may also improve workflow efficiency in selected clinical settings. Despite these promising findings, the limitations of FAPI PET should not be overlooked. Its imaging profile primarily reflects stromal cell activation and extracellular matrix remodeling within the bowel wall. Therefore, tracer uptake cannot be directly equated with the intensity of acute inflammatory activity [23,24]. Moreover, FAP lacks absolute disease specificity. False-positive uptake may occur in other benign inflammatory conditions, including esophagitis [37], chronic colitis [38], and ischemic colitis [39]. Therefore, interpretation in clinical practice requires careful correlation with the patient’s clinical history and endoscopic findings. Disease Activity and Burden Quantification Assessment of disease activity relies not only on lesion identification but also on the reproducible quantification of disease burden to facilitate severity stratification and longitudinal follow-up [40]. 18F-FDG PET/CT-derived SUVmax and volumetric global parameters provide noninvasive quantitative estimates of intestinal metabolic burden and demonstrate significant correlations with the Mayo score, histologic findings, and fecal biomarkers [41]. A meta-analysis showed that the pooled sensitivity, specificity, and inflammatory lesion detection rate of 18F-FDG PET for active inflammatory involvement in CD were 76%, 81%, and 89%, respectively. SUVmax was higher in inflamed than in noninflamed bowel segments and exhibited a correlation with C-reactive protein, indicating that FDG-derived quantitative parameters may reflect the burden of inflammatory activity [22]. Debus et al [18] also showed that 68Ga-FAPI PET/CT may reflect disease-activity-related stromal activation in both UC and CD. Using endoscopy as the reference standard, all patients with active disease had at least 1 strongly FAPI-positive lesion; only 4 of 14 patients with inactive disease had positive findings. Additionally, lesion SUVmean, SUVmax, and FAPI volume were all significantly higher in active disease than in inactive disease. These findings suggest that this technique accurately reflects fibroblast activation within the bowel wall and may be valuable for dynamic disease monitoring. Recent head-to-head studies have begun to shift PET evaluation in CD beyond binary interpretation toward quantification of the whole-bowel disease burden [31]. Three-dimensional global indices, such as molecular inflammatory volume and total intestinal uptake, have been proposed as candidate imaging biomarkers within a treat-to-target framework. These metrics have shown correlations with high-sensitivity C-reactive protein and the Simple Endoscopic Score for CD [31]. Additionally, 68Ga-FAPI-04 PET/CT may provide incremental value for detecting early or mild-to-moderate lesions in selected cohorts. Chen et al [36] reported a higher detection rate for these subtle lesions (89.3%) compared with the rate using conventional CTE (78.6%). For assessment of UC activity, preliminary prospective data suggest that 18F-FAPI PET/CT is a promising noninvasive imaging approach. One study showed that it outperformed 18F-FDG PET/CT in evaluating intestinal lesions and demonstrated stronger correlations with endoscopy, contrast-enhanced abdominal CT, and clinical biomarkers [42]. Mechanism-specific tracers may further expand PET-based disease activity assessment, although their clinical role remains preliminary. For example, (4S)-4-(3-18F-fluoropropyl)-L-glutamate (18F-FSPG) PET/CT may provide complementary biological information regarding immune cell-related pathways that is distinct from FDG [43]. Similarly, tracers targeting immune effector molecules such as granzyme B have shown potential for assessing active IBD and treatment response [30]. Taken together, these mechanism-targeted approaches represent promising future directions for disease severity stratification based on immune pathways and clinical phenotypes. Despite these advances, methodological heterogeneity in acquisition protocols and image segmentation methods, such as region-of-interest delineation, remains a major obstacle to routine clinical implementation [34,35]. Moreover, a single mechanism-targeted tracer is unlikely to capture the full pathologic spectrum of CD, in which transmural inflammation and chronic fibrotic remodeling frequently coexist [31]. Consequently, PET-derived quantitative metrics should be interpreted within a multimodal framework that incorporates cross-sectional imaging (MRE and CTE) and biochemical markers. Finally, multicenter prospective studies are needed to anchor PET-based quantitative thresholds to clinically meaningful outcomes, such as deep remission and first surgical intervention. Establishment of these benchmarks is essential before such metrics can be routinely used to refine IBD severity stratification [31,44]. Stricture Phenotype Stratification The clinical management of stricturing CD largely depends on identifying the predominant stricture component, whether inflammatory or fibrotic—this distinction guides decisions regarding biologic therapy escalation, endoscopic dilation, or surgical evaluation [45]. Although conventional cross-sectional imaging can demonstrate bowel wall thickening, its ability to characterize the inflammation-fibrosis continuum at the molecular level remains limited [46]. Recently, FAPI PET/CT has emerged as a promising molecular imaging technique for evaluation of intestinal fibrosis in CD [46]. A meta-analysis found that FAPI PET achieved sensitivity and diagnostic accuracy exceeding 90% for detecting intestinal fibrosis [22]. Additionally, tracer uptake intensity was strongly associated with histologic fibrosis grade, suggesting that FAPI PET reflects stromal activation associated with fibrogenesis. Scharitzer et al [23] confirmed these findings using 68Ga-FAPI PET/MRE. Their study demonstrated a correlation between tracer uptake and intestinal fibrosis severity, supporting a potential role for FAPI imaging in differentiating inflammatory from fibrotic lesion components. Intriguingly, increased FAPI uptake has been reported in CD-affected bowel, whereas little or no significant uptake has been observed in UC [47]. These findings suggest that stromal activation and extracellular matrix remodeling can provide complementary information for disease characterization beyond conventional morphologic imaging. Prospective head-to-head studies support the potential value of FAPI PET for stricture phenotyping in CD [24,35]. With regard to the early detection and grading of fibrosis, FAPI demonstrated better diagnostic performance than 18F-FDG and performance comparable to magnetization transfer imaging in the reported cohorts [35]. These findings suggest that FAPI can detect early fibrotic remodeling that is less apparent on FDG PET [35]. In anastomotic strictures, combined 68Ga-FAPI-46 and 18F-FDG PET/CT demonstrated complementary uptake patterns. FAPI uptake corresponded more closely to the degree of fibrosis on immunohistochemistry, whereas 18F-FDG uptake better reflected inflammatory activity [24]. This dual-tracer pattern may support component-level assessment of mixed strictures [24]. Additional prospective data extend this concept to complex CD lesions: those associated with strictures or fistulas showed increased uptake with both tracers, but overall diagnostic performance favored FAPI [31]. Such findings suggest that FAPI PET can help identify fibrosis-predominant or actively remodeling disease. Furthermore, it may provide adjunctive information for treatment planning, including guidance for endoscopic dilation, surgical evaluation, or clinical trial enrollment [31]. Dynamic 68Ga-FAPI-46 PET/CT may further refine lesion characterization. Positive IBD lesions demonstrated 2 time-activity curve patterns: a continuously increasing pattern and an early-peak plateau pattern. Time-to-peak thresholds above and below 1800 seconds may provide a potential noninvasive approach for stratifying intralesional inflammatory-fibrotic heterogeneity [18]. However, FAPI uptake should be interpreted cautiously. Intestinal strictures in CD often contain both inflammatory and fibrotic components. Therefore, a single FAPI uptake signal cannot be directly translated into a precise pathologic measure, such as the exact proportion of fibrosis [48]. False-positive uptake can also occur during physiologic stromal activation, including mucosal repair and ulcer healing [35]. Accordingly, accurate stricture phenotyping requires integration of molecular imaging findings with the clinical course, endoscopic assessment, and conventional cross-sectional imaging to avoid overinterpretation [36,46]. Longitudinal Therapeutic Monitoring The theoretical advantage of using PET/CT for therapeutic evaluation is that changes in metabolic and stromal activity may precede macroscopic morphologic changes [49]. In recent years, multiple studies have shown that global PET/CT burden indices are correlated with objective measures of disease activity, providing a potential methodological basis for longitudinal follow-up within a treat-to-target framework [49]. 18F-FDG PET/CT may serve as a noninvasive tool for evaluating therapeutic efficacy because intestinal tracer uptake is positively correlated with inflammatory cytokine levels, and reduced uptake after pharmacologic intervention may serve as an imaging marker of treatment response [50]. Spier et al [51] performed 18F-FDG PET/CT before and after treatment in patients with IBD. They found that active bowel segments with high pretreatment uptake exhibited reduced or absent uptake after therapy, paralleling symptomatic improvement. These findings highlight the potential of this modality for monitoring disease activity and treatment response [51]. Other studies in patients with known or suspected IBD have similarly shown that 18F-FDG PET/CT can provide adjunctive information for clinical assessment and treatment planning [52]. SUV-based PET parameters may provide quantitative information for longitudinal monitoring in CD. These parameters have been significantly correlated with high-sensitivity C-reactive protein and the Harvey-Bradshaw Index in both cross-sectional and longitudinal analyses [40]. Moreover, reductions in SUV-related metrics significantly differed between clinical responders and nonresponders, suggesting that FDG PET/CT can reflect changes in inflammatory activity over time [40]. Epelboym et al [49] also evaluated 18F-FDG PET/CT in patients with CD receiving anti-tumor necrosis factor-α therapy. Lesion SUVratio significantly decreased as early as 2 weeks after treatment; this early metabolic response was strongly associated with subsequent steroid-free clinical remission. These findings suggest that low-dose 18F-FDG PET/CT can help identify early treatment response before anti-tumor necrosis factor-α reinduction. Conversely, the absence of an early metabolic decline may indicate primary biologic treatment failure or an increased risk of subsequent surgery [49]. Additionally, some patients with refractory CD do not respond to or cannot tolerate conventional medical therapy and require specialized interventions, such as granulocyte and monocyte adsorptive apheresis. In these clinical scenarios, longitudinal changes in 18F-FDG PET uptake may also reflect changes in the intestinal inflammatory burden, providing a noninvasive approach for evaluation of selected salvage therapies [53]. In longitudinal treatment response monitoring, routine clinical implementation of PET/CT remains constrained by the lack of standardized evaluation frameworks [44]. Current studies continue to show substantial inconsistency in the definition of imaging response, whether based on clinical, endoscopic, or transmural remission. Furthermore, there is no consensus regarding the optimal timing of follow-up examinations or the quantitative thresholds for metabolic decline [44,54]. Future large-scale cohort studies should evaluate the dynamic evolution of disease and incorporate changes in 3-dimensional global parameters, such as total intestinal uptake and molecular inflammatory volume, as prespecified imaging endpoints. These parameters should be validated against deep healing and hard clinical outcomes, including avoidance of bowel resection, before broadly applicable consensus standards for imaging follow-up can be established [34,35]. Characterization of Complex Complications Major complications of IBD include fistulas, abscesses, luminal strictures, and perforation [44,45]. These complications are more common in CD than in UC because CD is characterized by transmural inflammation [44,45]. At present, structural assessment of penetrating complications, such as abscesses and perforation, primarily relies on CT or MRI; PET/CT mainly serves as a problem-oriented complementary modality [44]. By integrating metabolic imaging with anatomic localization, PET/CT may support the noninvasive quantification of inflammatory activity and delineation of disease extent. This capability partly addresses the limitations of endoscopy and conventional imaging in evaluating strictured bowel segments and identifying deep fistulas or abscesses [44,55]. 18F-FDG PET is highly sensitive to infection and inflammation, but physiologic and nonspecific intestinal uptake often interferes with image interpretation [56]. Therefore, in the assessment of complications such as abscesses, 18F-FDG is primarily used to identify metabolically active foci. However, definitive diagnosis and localization require correlation with morphologic findings on CT or MRI [56]. One study showed that the SUVmax of perianal fistulas was significantly higher than that of the liver and anal canal. The SUVmax of St James grade 1 fistulas was also significantly lower than that of grade 2 and grade 4 fistulas. These findings suggest that 18F-FDG uptake can provide useful information to assess fistula activity [57]. In penetrating disease, PET/CT may also reflect the dynamic evolution of inflammation over time. A longitudinal follow-up study demonstrated an overall decline in the SUVmax of perianal fistulas on serial PET/CT examinations, consistent with decreasing inflammatory activity [55]. Additionally, among patients with incidental focal 18F-FDG uptake in the small bowel despite no obvious abnormality on CT, up to one-fifth subsequently required clinical intervention. This finding suggests that 18F-FDG PET/CT can serve as a potential early warning indicator and may help guide targeted endoscopic or cross-sectional imaging evaluation, particularly in patients with concomitant malignancy risk or diagnostic uncertainty [58]. Compared with 18F-FDG, FAPI may provide greater sensitivity for detecting stromal remodeling and fibrotic activity in selected lesions. This characteristic offers additional information for the evaluation of complex complications [35]. A prospective study showed that 68Ga-FAPI-04 PET/CT achieved higher sensitivity and specificity than 18F-FDG PET/CT for assessing complex structural abnormalities in CD, such as strictures and fistulas [31]. These findings suggest that FAPI PET/CT can help identify biologically active or remodeling lesions and provide adjunctive information for treatment planning, including treatment escalation or surgical evaluation [31]. Zheng et al [59] reported high detection rates for 68Ga-FAPI-04 PET/CT in complicated CD. It detected all evaluated fistulas (7/7), strictures (6/6), and abscesses (3/3) and, along with enterography, was the only modality to detect sinus tracts (1/1). It also detected creeping fat infiltration in all cases (10/10), outperforming 18F-FDG PET/CT (3/10), enterography (9/10), and intestinal ultrasonography (6/10). These results suggest potential incremental value for assessing complex complications and mesenteric involvement in CD. Overall, PET/CT has been investigated across key clinical scenarios in IBD, including disease detection, metabolic burden assessment, phenotype characterization, therapeutic monitoring, and complication evaluation (Table 1). These findings support its complementary metabolic value, although clinical implementation requires further standardization and prospective validation. Clinical Applications of Integrated PET/MRI Integrated Assessment of Diagnostic Performance Although PET/MRI has not yet been routinely implemented in clinical practice, it represents an advanced hybrid imaging modality that integrates metabolic, anatomic, and functional information in a single examination. This integrated approach may support lesion localization and comprehensive assessment of disease activity in IBD, particularly CD [6,67]. In a comparative study using surgical pathology as the reference standard, PET/MR demonstrated higher diagnostic accuracy for detecting active inflammation than PET alone (91.0% vs 84.0%) or MRI alone (91.0% vs 83.0%) and significantly improved specificity compared with PET alone (93.0% vs 74.0%) [68]. Another study evaluated the relationship between 18F-FDG PET/MRE parameters and inflammatory biomarkers in CD. By integrating the apparent diffusion coefficient and molecular inflammatory volume into the magnetic resonance index of activity (MaRIA) score, the AUC of the combined diagnostic model increased from 0.63 to 0.92. Using a cutoff value of 447, the model achieved a sensitivity of 83% and specificity of 100% [69]. This improvement supports the potential value of multiparametric PET/MRE integration for disease activity stratification. Li et al [67] also evaluated the clinical value of multiparametric assessment with 18F-FDG PET/MR through a series of studies. Their work showed that bowel wall thickness and the comb sign were important predictors of active inflammation in CD. Among the evaluated parameters, SUVmax achieved the highest diagnostic performance, with an AUC of 0.81. SUVmax outperformed individual MRI parameters, including bowel wall thickening and the apparent diffusion coefficient. PET quantitative parameters also effectively discriminated segmental inflammation severity; statistically significant differences were observed across severity groups (P < 0.05) [67]. The same research team subsequently developed a hybrid PET/MR index in a cohort of 52 patients with recurrent CD by integrating MRI features, including bowel wall thickness, edema, and ulcers, with the PET-derived SUVmax ratio. For predictions of active and severe inflammation, this index demonstrated sensitivity comparable to that of the MaRIA and Clermont scores. However, it achieved higher specificity and overall diagnostic accuracy in the assessment cohort [70]. These results indicate that a multiparametric PET/MR index may improve the noninvasive assessment of CD activity compared with MRI-based indices alone [70]. Evidence in UC also supports the potential value of PET/MR. In a prospective study of 50 patients, endoscopic and histologic inflammatory activities were assessed using the Mayo endoscopic subscore and Nancy histologic index, respectively [71]. The specificity of 18F-FDG PET was 84.3% without bowel preparation and 59.5% after bowel preparation, whereas 18F-FDG PET/MR without prior bowel preparation achieved an overall accuracy of 91.2% [71]. In the same year, the same research team compared PET/MR with fecal biomarkers in assessment of UC activity. Using endoscopy as the reference standard, both approaches identified active disease; PET/MR demonstrated higher diagnostic accuracy and stronger correlations with endoscopic scores for predicting moderate-to-severe UC activity, relative to conventional fecal biomarkers [72]. Notably, Tenhami et al [73] performed 18F-FDG PET/MRE in 10 patients with relapsed or suspected IBD, using histology as the reference standard; they found that SUVmax was closely associated with inflammatory activity. Severe inflammation was associated with a pronounced increase in SUVmax. Moderate inflammation showed only a slight, nonsignificant increase relative to background, whereas mild inflammation showed no appreciable difference. A recent meta-analysis including 14 studies showed that 18F-FDG PET/CT and PET/MR had comparable overall diagnostic performance for the evaluation of IBD, with summary receiver operating characteristic AUC values of 0.92 and 0.95, respectively [34]. These pooled findings support the potential role of PET-based hybrid imaging as a noninvasive adjunct for disease monitoring, although heterogeneity among studies should be considered. Transmural Inflammation and Penetrating Lesions Transmural inflammation is a key pathologic feature that distinguishes CD from superficial intestinal disorders. Inflammation may involve the full thickness of the bowel wall and extend into the mesentery and surrounding tissues. Consequently, disease progression often leads to penetrating complications such as fistulas, inflammatory masses, and abscesses [74]. Conventional endoscopy is inherently limited because it directly visualizes only the mucosal layer. Therefore, it cannot comprehensively assess full-thickness bowel wall involvement or deep extraintestinal lesions [6]. PET/MRE enables the co-registration of PET-derived metabolic information with high-resolution anatomic and functional MRI features, including diffusion-weighted imaging and contrast-enhanced sequences. This integrated approach may support quantitative assessment of bowel wall inflammatory burden and extramural complications. Furthermore, it might provide complementary imaging information for transmural phenotypic stratification and localization of complex lesions in CD [68,75]. Pellino et al [76] showed that PET/MR was largely concordant with PET/CT for detecting active inflammation in CD. Notably, PET/MRI demonstrated improved correlation with the pathologic assessment of bowel wall structural remodeling. Additionally, PET/MRE was able to sensitively detect additional lesions located extraintestinally or distant from the primary involved bowel segment. This capability may provide incremental information for preoperative surgical planning [76]. A prospective study focusing on small-bowel CD demonstrated that, at an 18F-FDG SUVmax cutoff of 2.5, PET/MRE yielded an AUC of 0.81 for detecting active transmural inflammation [77]. In complex pelvic or perianal penetrating disease, PET/MR may improve lesion characterization by helping distinguish active inflammatory fistulas from physiologic distal bowel uptake and by clearly delineating the metabolic extent of suppurative masses. When interpreted along with conventional anatomic imaging and clinical findings, this information may help guide surgical drainage or debridement planning in selected cases [78]. Furthermore, composite PET/MR quantitative indices that integrate metabolic activity with measures of restricted water diffusion have preliminarily demonstrated higher diagnostic performance than conventional MR severity indices for assessing severe transmural ulceration [70]. Concurrently, artificial intelligence (AI)-based multiparametric clustering algorithms for PET/MR are being gradually introduced. In the future, these advanced tools may enable adaptive lesion delineation and precise 3-dimensional grading of regions with severe transmural inflammation [79]. Stricture Phenotyping In stricturing CD, differentiation of inflammatory, fibrotic, and mixed components remains clinically important for phenotype characterization and treatment planning [76]. Inflammation-predominant strictures may be reversible with medical therapy, whereas fibrotic strictures often require surgery. Because CD progresses in a transmural manner, inflammatory exudation and fibrotic deposition frequently coexist in an intertwined pattern. This complexity makes it difficult for any single conventional imaging modality to provide an integrated qualitative and quantitative assessment [67]. By combining the metabolic sensitivity of PET with the superior soft-tissue contrast of MRI, 18F-FDG PET/MRE may support multidimensional assessment of transmural lesions with respect to morphology, functional activity, and tissue phenotype [11]. In terms of multimodal parameter integration, composite quantitative biomarkers derived from PET/MRE have shown potential advantages [80]. Catalano et al [80] demonstrated that SUVmax and composite metrics combining SUVmax with MRI parameters significantly differed across the pure fibrosis, fibrosis with active inflammation, and pure inflammation groups. Among the evaluated metrics, the composite parameter apparent diffusion coefficient × SUVmax (cutoff value < 3000) showed the best discriminative performance (accuracy, 0.71) and outperformed single-modality parameters. For the specific identification of irreversible fibrosis, novel molecular tracers have further expanded the diagnostic scope [23]. Scharitzer et al [23] also demonstrated that lesion SUVmax on 68Ga-FAPI PET/MRE was strongly positively correlated with histologic fibrosis scores, with an AUC of up to 0.94 for distinguishing mild from moderate-to-severe fibrosis. Additionally, a recent prospective study evaluated the collagen-targeted tracer gallium-68-labeled collagen-binding peptide 8 (68Ga-CBP8). The results showed prominent focal uptake in pathologically confirmed mixed inflammatory-fibrotic strictures, whereas no appreciable uptake was observed in nonfibrotic strictures. Notably, this tracer achieved a sensitivity and specificity of 100% for identifying the fibrotic component [81]. Preliminary application of these novel tracers provides highly promising imaging support for the noninvasive differentiation of overlapping pathologic components [81]. Despite the considerable potential of PET/MR for stricture phenotyping, its routine clinical use remains hindered by high cost, prolonged acquisition time, and restricted applicability in emergency settings such as bowel obstruction [76]. Additionally, current evidence is largely derived from small, single-center cohorts; cutoff values used to define overlapping inflammatory-fibrotic signals remain heterogeneous across different hardware platforms and tracers. Large multicenter studies are needed to establish standardized consensus criteria for clinical interpretation [82]. Monitoring of Therapeutic Response In the modern clinical management of IBD, particularly CD, the treat-to-target strategy has extended therapeutic goals beyond clinical symptom relief to include histologic and even transmural healing [25,83]. Against this background, the value of longitudinal monitoring with multimodal imaging has gained increasing interest [11]. Compared with anatomic imaging alone, integrated PET/MRI combines morphologic features, such as tissue edema and restricted diffusion, with molecular metabolic information in a single examination. This multimodal approach may allow earlier recognition of tissue-level biological responses before overt morphologic changes become apparent. Consequently, it provides complementary support for dynamic treatment response assessment and therapeutic adjustment [11,76]. For longitudinal quantitative monitoring of therapeutic response, a prospective clinical study showed that, after 3 months of standard immunosuppressive and biologic therapy, patients with CD exhibited significant reductions in SUVmax and SUVmean in affected small-bowel segments compared with baseline (P < 0.05). Improvements in these metabolic parameters were correlated with declines in fecal calprotectin and the simplified MaRIA score. Such correlations support the potential role of 18F-FDG PET/MR as a noninvasive quantitative approach for assessing treatment response and monitoring disease remission [84]. In a secondary analysis of a randomized trial in UC, 18F-FDG PET/MR differentiated bowel segments with persistent histologic inflammation despite apparent endoscopic remission from those with complete endoscopic and histologic remission. The bowel-to-liver SUVmax quotient (SUVmaxQuot) was correlated with the Mayo endoscopic subscore. These findings suggest that 18F-FDG PET/MR can serve as a potential noninvasive alternative to endoscopy in selected clinical or research settings [71]. Furthermore, in cohorts of children and adolescents with refractory IBD, serial PET/MRI follow-up demonstrated moderate overall diagnostic performance (AUC = 0.77). Longitudinal changes in multiparametric scores effectively distinguished clinical responders from nonresponders, helping clinicians discontinue ineffective treatment in a timely manner [12]. Despite its promise for treatment response monitoring, the routine clinical implementation of PET/MRI is constrained by several factors. Due to interference from bowel peristalsis and intraluminal contents, its specificity for assessing segmental colorectal inflammation remains relatively low (0.57). Moreover, its ability to detect superficial micro-ulcers has not shown superiority to that of conventional high-resolution MRI [12]. Current composite response scores heavily rely on time-consuming manual measurements across multiple sequences, making them difficult to efficiently implement in high-throughput routine clinical practice [75]. Advantages in Pediatric Patients and Long-Term Follow-Up Pediatric and adolescent IBD is often characterized by more extensive disease involvement and a more aggressive course, creating a clinical need for frequent longitudinal imaging to monitor disease progression [6]. Conventional radiation-based imaging techniques are associated with cumulative ionizing radiation exposure. This exposure may increase the long-term risk of secondary malignancies in children and young adults. Consequently, use of these imaging techniques is limited in pediatric populations and in young adults requiring prolonged follow-up [85]. As a low-radiation multimodal imaging modality, integrated PET/MRI can reduce overall radiation exposure by as much as 80% while simultaneously providing high-resolution soft-tissue morphology and metabolic information in a single examination [86]. Additionally, this combined imaging approach may reduce the need for repeated imaging studies and lessen potential risks associated with repeated sedation or general anesthesia, including neurocognitive impairment and aspiration [87]. In recent years, prospective studies in pediatric IBD populations and cohorts requiring long-term follow-up have further strengthened evidence supporting the clinical application of PET/MRI [88]. A prospective clinical accuracy study including children and adolescents aged 8 to 17 years with IBD showed that, for segment-by-segment detection of active intestinal inflammation, PET/MRI achieved a sensitivity of 83%, specificity of 57%, and AUC of 0.77 [12]. Moreover, during longitudinal follow-up, concurrent declines in MRI- and PET-derived quantitative scores were associated with improvements in clinical response [12]. Comparative studies have also confirmed that, relative to conventional 18F-FDG PET/CT, PET/MR may offer particular advantages for assessing inflammatory lesions in adolescents because of its superior soft-tissue resolution and substantially lower radiation exposure [88]. From a translational perspective, multimodal composite biomarkers based on PET and MRI may improve cross-sectional assessment of disease activity and contribute to the noninvasive quantification of intestinal inflammatory burden during long-term follow-up [68]. Despite its advantages in radiation safety and multidimensional diagnostic assessment for pediatric IBD staging and long-term monitoring, the broader clinical adoption of PET/MRI remains limited by technical and economic constraints [77]. Accurate co-registration of PET with multiparametric MRI requires prolonged acquisition times, and bowel peristalsis is susceptible to the generation of motion artifacts, posing a particular challenge in younger children with limited compliance [12]. Most existing pediatric PET/MRI studies are based on small, single-center cohorts. Moreover, their diagnostic performance has not yet shown clear superiority to that of PET or MRI alone, further limiting widespread clinical implementation [12]. Collectively, PET/MRI has been evaluated across key clinical scenarios in IBD, including integrated disease assessment, transmural lesion characterization, stricture phenotyping, treatment monitoring, and pediatric and long-term follow-up applications (Table 2). These findings support its value as a multiparametric, low-radiation imaging modality while underscoring the need for further validation. Challenges and Limitations Although PET/CT and PET/MRI have shown promising potential for the noninvasive assessment and molecular visualization of IBD, their translation into routine clinical practice continues to face multiple practical barriers [6]. With respect to target specificity and pathologic phenotyping, conventional 18F-FDG PET is susceptible to interference from high physiologic background activity. Furthermore, highly variable glucose uptake throughout the gastrointestinal tract often overlaps with the abnormal metabolic pattern of active inflammation, thus reducing diagnostic specificity for subtle mucosal lesions [44]. Additionally, the metabolic patterns of acute inflammation, chronic mixed lesions, and predominantly fibrotic strictures may overlap. Therefore, conventional metabolic tracers alone are insufficient to definitively distinguish pathologic remodeling patterns within the bowel wall [76,91]. Considering the need to balance imaging safety and clinical feasibility, the cumulative ionizing radiation exposure associated with conventional PET/CT limits its use in young and pediatric patients who require frequent long-term follow-up [85]. Although integrated PET/MRI can substantially reduce radiation exposure, its relatively long acquisition time for a single abdominopelvic examination, often exceeding 45 minutes, may compromise tolerability in critically ill patients and young children. It also increases susceptibility to motion artifacts caused by respiratory motion and intrinsic bowel peristalsis, which may affect the accuracy of quantitative parameters such as lesion SUVmax [12]. A further technical barrier is the lack of robust attenuation correction and standardized imaging frameworks. Unlike CT, integrated PET/MRI does not provide absolute electron density information. Moreover, attenuation correction in the abdomen and pelvis, which is derived from magnetic resonance sequences, remains inherently limited in handling complex gas-fluid interfaces within the bowel lumen. This limitation may lead to local underestimation of metabolic activity or attenuation-correction artifacts [67,68]. In addition to these technical challenges, no international consensus has been established regarding IBD-specific image acquisition protocols and quantitative interpretation criteria. Consequently, substantial heterogeneity persists across centers in the definition of diagnostic thresholds, further hindering incorporation into guideline-based clinical practice [6]. Clinical Applicability Across IBD Scenarios Given the heterogeneity of current evidence, PET-based imaging in IBD should be interpreted according to the clinical scenario, patient population, tracer biology, and technical feasibility rather than based on imaging modality alone. Table 3 provides an evidence-based framework that maps major PET-based approaches to clinical scenarios with relatively strong evidence, adjunctive or selected use, and investigational or insufficiently validated roles. It also distinguishes key practical contexts, including adult versus pediatric follow-up, inflammatory burden assessment versus fibrosis-oriented phenotyping, and evaluation of selected complications versus routine first-line monitoring. Finally, it summarizes key considerations relevant to clinical interpretation and future validation. Future Directions Novel Molecular Tracers As molecular imaging in IBD evolves from simple quantification of inflammatory burden toward in vivo visualization of the immune microenvironment and therapeutic targets, novel molecular probes are showing promising translational potential [10,92]. In early small-sample clinical studies, 68Ga-pentixafor, which targets C-X-C chemokine receptor 4 (CXCR4), was able to depict active intestinal lesions and concomitant mesenteric lymphadenitis without the need for fasting or bowel preparation. These findings suggest that it can provide complementary molecular information for the assessment of active inflammation [60]. For the detection of early immune activation, a granzyme B-targeted peptide probe, gallium-68-labeled NOTA-conjugated granzyme B-binding peptide (68Ga-NOTA-GZP), has shown preliminary potential for monitoring disease activity and early therapeutic response in preclinical models [30]. Additionally, immuno-PET using monoclonal antibodies labeled with long-half-life radionuclides, such as zirconium-89-labeled desferrioxamine-conjugated infliximab (89Zr-DFO-infliximab), has enabled noninvasive visualization of target molecules in preclinical studies, achieving colon-to-muscle uptake ratios greater than 10. This approach may provide a promising imaging strategy for future target occupancy monitoring and companion diagnostics for biologic therapies [93]. Overall, these novel tracers expand the mechanistic scope of PET imaging in IBD, although their clinical value requires further validation [93]. Hardware Advances and Sequence Innovation To address the challenges of cumulative radiation exposure during frequent follow-up and motion artifacts caused by prolonged scan times, ongoing advances in nuclear medicine hardware and imaging sequences have revealed new technical opportunities [94,95]. By greatly improving geometric detection efficiency, long-axial-field-of-view PET/CT may enable ultralow-dose, high-resolution imaging with shorter acquisition times, reducing radiation exposure by up to 90% while using administered activities as low as approximately 0.57 MBq/kg. This capability substantially reduces the radiation burden in pediatric patients. Furthermore, the shorter acquisition time mitigates motion artifacts related to bowel peristalsis and respiratory motion [95]. Real-time MR-based motion-correction techniques have been developed to address complex nonrigid motion during simultaneous abdominal PET/MR without requiring external respiratory surrogates. Motion phases and phase-to-phase nonrigid motion fields derived from dynamic MR data may reduce motion artifacts and improve PET reconstruction quality [96]. Empowerment by Deep Learning and AI To address the challenges of stringent dose constraints and attenuation correction, deep learning-based AI methods may provide new approaches for PET image optimization [97,98]. To reduce attenuation-correction bias in PET/MR resulting from the lack of CT-derived electron density information, deep convolutional neural network-based models have been used to generate pseudo-CT attenuation maps from routine MR sequences. One study indicated that this approach reduced SUVmax quantification error in osseous lesions from 20.0% to 3.8%. Such substantial improvement highlights its potential to enhance the quantitative accuracy of metabolic activity assessment [99]. A prospective study in CD showed that, even under an ultra-low-dose protocol retaining only 20% of standard PET counts, deep learning-enhanced reconstruction restored severely noisy PET images to a level at which quantitative parameters and qualitative assessments approached those of full-dose imaging. These findings support the technical feasibility of dose-reduced PET protocols for longitudinal monitoring in younger patients [97]. Furthermore, a unified, data-driven respiratory motion-correction method based on deep learning has been reported to reduce PET blurring, attenuation-correction mismatch, and PET/CT misregistration, thus improving lesion detectability, image quality, and SUV quantification accuracy in thoracoabdominal PET/CT [98]. Looking ahead, AI-driven radiomic feature extraction and high-dimensional classification models may help reduce interobserver variability and contribute to the standardization of molecular imaging assessment in IBD [100]. Conclusions Hybrid molecular imaging, including PET/CT and PET/MRI, may serve as a promising adjunct to conventional endoscopy and standard cross-sectional imaging in IBD. Rather than replacing established modalities, these techniques show potential clinical value in specific scenarios, particularly for the noninvasive quantification of inflammatory burden, fibrosis-oriented stricture phenotyping, evaluation of complex complications, and therapeutic monitoring within a treat-to-target framework. However, their routine clinical implementation remains constrained by the lack of standardized protocols, heterogeneous quantitative thresholds, and insufficient large-scale prospective validation. Future advances in novel targeted tracers, ultra-low-dose long-axial-field-of-view systems, and AI-driven image analysis may help overcome these translational barriers. Ultimately, prospective multicenter studies are needed to establish consensus guidelines, validate PET-derived biomarkers, and define the precise clinical indications for these advanced imaging modalities in individualized IBD management.